PALISADE BIO, INC.
Business
Palisade Bio is a clinical-stage biopharmaceutical company developing once-daily oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. The company's lead product candidate, PALI-2108, is being evaluated in clinical trials for inflammatory bowel disease, including ulcerative colitis and Crohn's disease, with a focus on fibrostenosing Crohn's disease. Palisade operates as a single clinical-stage entity advancing its pipeline through internal research and contract manufacturing partnerships.
Summary from 10-K filed 2026-03-20
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 10 | 9 | 7 | 7 | 2 | |
| General and administrative | 8 | 6 | 6 | 9 | 9 | |
| Total operating expenses | 18 | 15 | 13 | 16 | 42 | |
| Loss from operations | −18 | −15 | −13 | −16 | −42 | |
| Interest expense | −10,000 | −12,000 | — | — | — | |
| Other income, net | 1 | 433,000 | 785,000 | 3 | 47,000 | |
| Total other income, net | 1 | 421,000 | 770,000 | 1 | 15 | |
| Net loss | −17 | −14 | −12 | −14 | −27 | |
| Basic weighted average shares used in computing net loss per common share | 56 | 1 | 456,014 | 880,311 | 186,195 | |
| Diluted weighted average shares used in computing net loss per common share | 56 | 1 | 456,014 | 880,311 | 186,958 | |
| Basic net loss per common share | −0.3 | −10.19 | −27.01 | −16.53 | −142.95 | |
| Diluted net loss per common share | −0.3 | −10.19 | −27.01 | −16.53 | −169.74 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-08-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 133 | 10 | 12 | — | 12 | |
| Prepaid expenses and other current assets | 836,000 | 673,000 | 896,000 | — | 2 | |
| Total current assets | 134 | 10 | 13 | — | 15 | |
| Restricted cash | 55,000 | 26,000 | 26,000 | — | 26,000 | |
| Property and equipment, net | 0 | 3,000 | 10,000 | — | 10,000 | |
| Operating lease right-of-use asset | 0 | 84,000 | 198,000 | — | 300,000 | |
| Other noncurrent assets | 68,000 | 273,000 | 490,000 | — | 694,000 | |
| Total assets | 134 | 11 | 14 | — | 16 | |
| Accounts payable | 767,000 | 1 | 698,000 | — | 2 | |
| Accrued liabilities | 2 | 1 | 831,000 | — | 574,000 | |
| Accrued compensation and benefits | 1 | 722,000 | 778,000 | — | 486,000 | |
| Current portion of operating lease liability | 0 | 90,000 | 121,000 | — | 105,000 | |
| Share liability | 313,000 | 0 | — | — | — | |
| Insurance financing debt | 71,000 | 79,000 | 158,000 | — | 88,000 | |
| Total current liabilities | 5 | 3 | 3 | — | 3 | |
| Warrant liability | 0 | 2,000 | — | — | — | |
| Derivative liability | 62,000 | 0 | 2,000 | — | 61,000 | |
| Contingent consideration obligation | 266,000 | 150,000 | 61,000 | 200,000 | 0 | |
| Total liabilities | 5 | 3 | 3 | — | 3 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Common stock, $0.01 par value; 300,000,000 and 280,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 159,444,017 and 2,768,646 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 2 | 27,000 | 6,000 | — | 30,000 | |
| Additional paid-in capital | 281 | 143 | 133 | — | 122 | |
| Accumulated deficit | −153 | −136 | −122 | — | −109 | |
| Total stockholders' equity | 129 | 7 | 11 | — | 12 | |
| Total liabilities and stockholders' equity | 134 | 11 | 14 | — | 16 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 3,000 | 3,000 | 4,000 | 3,000 | — | |
| Non-cash operating lease expense | 84,000 | 114,000 | 102,000 | 164,000 | — | |
| Non-cash expense for the issuance of common stock (Note 5) | 125,000 | 0 | — | — | — | |
| Recurring fair value measurements of liabilities | 349,000 | −54,000 | 145,000 | — | — | |
| Payment of contingent consideration obligation | −235,000 | 0 | — | — | — | |
| Issuance of common stock to vendors | 0 | 135,000 | 0 | — | — | |
| Write-off of deferred equity issuance costs | 75,000 | 0 | — | — | — | |
| Loss on disposal of property and equipment | 0 | 4,000 | 0 | — | — | |
| Stock-based compensation and related charges | 4 | 652,000 | 624,000 | 1 | 2 | |
| Other | −61,000 | 0 | −108,000 | −233,000 | −192,000 | |
| Prepaid and other current assets and other noncurrent assets | 529,000 | 750,000 | 705,000 | 1 | −1 | |
| Accounts payable and accrued liabilities | 624,000 | 818,000 | −492,000 | 399,000 | −2 | |
| Accrued compensation and benefits | 576,000 | −56,000 | 292,000 | −25,000 | −1 | |
| Operating lease liabilities | −90,000 | −121,000 | −105,000 | −151,000 | −168,000 | |
| Net cash used in operating activities | −11 | −12 | −11 | −13 | −15 | |
| Payments on insurance financing debt | −320,000 | −426,000 | −391,000 | −790,000 | −1 | |
| Proceeds from issuance of common stock and warrants, net of underwriting discounts and commissions | 128 | 8 | 9 | 14 | 5 | |
| Proceeds from the exercise of warrants | 8 | 3 | 3 | 2 | — | |
| Payment of warrant inducement issuance costs | −495,000 | −343,000 | 0 | — | — | |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | 19,000 | 11,000 | 17,000 | 0 | — | |
| Shares withheld for payment of employee withholding tax liability | 0 | −25,000 | 0 | — | — | |
| Net cash provided by financing activities | 134 | 10 | 11 | 15 | 25 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 124 | −3 | 49,000 | 2 | 10 | |
| Interest paid | 10,000 | 14,000 | 14,000 | 12,000 | 64,000 | |
| Equity issuance costs included in accounts payable and accrued liabilities | 46,000 | 0 | — | — | — | |
| Warrant inducement costs included in accounts payable and accrued liabilities | 0 | 176,000 | — | — | — | |
| Proceeds from the issuance of common stock included in other current receivables (Note 5) | 250,000 | 0 | — | — | — | |
| Fair value of common shares to be issued included in share liability (Note 5) | 250,000 | 0 | — | — | — | |
| Fair value of warrants issued to solicitation agent in warrant inducements (Note 5) | 233,000 | 94,000 | 0 | — | — | |
| Fair value of warrants issued to placement agents (Note 5) | 11 | 527,000 | 384,000 | — | — | |
| Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities | 0 | 37,000 | 6,000 | 0 | — | |
| Insurance financing debt included in prepaid and other current assets and other noncurrent assets | 312,000 | 347,000 | 461,000 | 784,000 | — | |
| Incremental fair value of modified or exchanged warrants (Note 5) | 9 | 2 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is PALISADE BIO, INC.'s CIK number?
PALISADE BIO, INC.'s SEC CIK number is 0001357459 (1357459). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PALISADE BIO, INC.'s SEC filings?
All of PALISADE BIO, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PALISADE BIO, INC. last report earnings?
PALISADE BIO, INC. (PALI) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001357459-26-000011). This is PALISADE BIO, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is PALISADE BIO, INC.'s most recent earnings 8-K?
PALISADE BIO, INC.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001357459-26-000011. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PALISADE BIO, INC.'s latest earnings 8-K →
Look up any company's CIK number →